Blood: Immune escape from PD-1 is a defining feature of large B-cell lymphoma rich in T-cells/tissue cells.

Large B-cell lymphoma (TCRLBCL), which is rich in T-cell/tissue cells, is an aggressive variant of dispersive large B-cell lymphoma (DLBCL), characterized by the memory of rare malignant B cells in powerful and ineffective immersion immune cells.
the basis of the immune escape mechanism of TCRLBCL is not clearly defined, there are no targeted treatment measures.
Griffin and others performed genetic and quantitative spatial analysis of PD-1/PD-L1 paths in multi-agency TCLRBCLs queues and found that in 64% of cases, malignant B cells carried an increase or amplification of the number of PD-L1/PD-L2 copies associated with the increase in PD-L1 expression.
Through targeted and unsuperpted spatial analysis of multi-parameter cell esotype data in tumor micro-environment, TCRLBCL is characterized by malignant B cells surrounded by TAM and PD-1 positive T cells with abnormally high expression of PD-L1 in tumor immunologic micro-environment.
, the unbiased aggregation of spatially differentiated immune characteristics distinguishes TCRLBCL from the associated B-cell lymphoma subtypes, including classic Hodgkin's lymphoma and DLBCL-NOS.
, the researchers observed that 3 out of 5 patients with relapse/resoicative TCRLBCL received clinical remission through PD-1 block therapy, including 2 complete remissions and 1 partial remission.
in summary, the results of this study show that the PD-1 signal is an immune escape signal of TCRLBCL, and also demonstrate the practicality of spatially distinguished immune characteristics to assist in diagnosis classification and to identify the priorities of immunotherapy for different tumor types.
.